Key result
Surgical treatment of benign cardiac tumors was successful with no relapses, while malignant tumors had a poor prognosis with an overall mortality of 27% over a median 44 months.
Why the study?
Cardiac tumors are rare, heterogeneous, and remain a diagnostic and therapeutic challenge, prompting an overview of surgical results over nearly 20 years at a tertiary care center.
Observational (n=55)
No
Surgical resection of benign cardiac tumors yields excellent long-term outcomes with no relapses, whereas malignant cardiac tumors carry a poor prognosis despite radical surgery.
Answers are grounded in this paper and cite their sources.
Retrospective series supports surgical feasibility in rare cardiac tumors; leaves open need for prospective multicenter data to guide practice.
INTRODUCTION: Cardiac tumors are rare and heterogeneous entities which still remain a diagnostic and therapeutic challenge. The treatment for most cardiac tumors is prompt surgical resection. We sought to provide an overview of surgical results from a series of consecutive patients treated at our tertiary care center during almost a 20-year experience. METHODS AND RESULTS: In this single center study, 55 consecutive patients with diagnosis of cardiac tumor underwent surgical treatment from January 2002 to April 2021. Of these, 23 (42%) were male and the mean age was 62 ± 12 years. Fifteen (27%) patients were symptomatic at the time of the diagnosis, mostly for dyspnea and palpitations. The most frequent benign cardiac tumor was myxoma (32; 58%), occurring mainly in the left atrium (31; 97%). Pleomorphic sarcoma was the most frequent primary malignant cardiac tumor (4; 7%), mainly located in the ventricles (1; 25% in the left ventricle; 2; 50% in the right ventricle). In all cases of benign tumors surgery was successful with no relapses. Two (50%) pleomorphic sarcomas showed subsequent relapses. After a median follow-up of 44 months, 15 (27%) patients died. Although malignant tumors presented a limited survival, benign tumors showed a very good prognosis. CONCLUSION: Cardiac tumors require a multidisciplinary approach to guarantee a prompt diagnosis and appropriate treatment. In our surgical experience, outcome after surgery of benign tumors was excellent, while malignant tumors had poor prognosis despite radical surgery.
No takes yet. Share an insight, caveat, or question.
Restivo et al. (2022) conducted an observational in Cardiac tumors (n=55). Surgical treatment was evaluated on Mortality. Surgical treatment of benign cardiac tumors was successful with no relapses, while malignant tumors had a poor prognosis with an overall mortality of 27% over a median 44 months.
Synapse has enriched 10 related papers. Consider them for comparative context: